Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Multicenter Prospective Evaluation of Diagnostic Potential of Flow Cytometric Aberrancies in Myelodysplastic Syndromes

Blood (2021) 138 (Supplement 1): 3995.

https://doi.org/10.1182/blood-2021-152298

Published: 2021

Journal Articles

From Mild Cytopenia to Overt MDS and AML, the Mutational Profile Predicts Progression, but Not Survival

Jakob Werner Hansen, MD, Morten Munk Johansen, MD, Maj Karoline Westman, MSc, Leonie Saft, MD PhD, Lene Dissing Sjö, MD PhD, Claus Werenberg Marcher, MD PhD, Mette Skov Holm, MD PhD, Marios Dimitriou, PhD, Mohsen Karimi, PhD, Klas Raaschou-Jensen, MD, Andreas Birkedal Glenthøj, MD PhD, Marianne Tang Severinsen, MD PhD, Eva Hellström-Lindberg, MD PhD, Mette Klarskov Andersen, MD DMSc, Kirsten Grønbæk, Professor, MD DMSc

Blood (2018) 132 (Supplement 1): 794.

https://doi.org/10.1182/blood-2018-99-110767

Published: 2018

Journal Articles

The Diagnostic Role of Flow Cytometry in Idiopathic Cytopenia of Unknown Significance (ICUS): A Single-Center Analysis of 79 Patients

Konstantinos Dimopoulos, MD, Olga Kristina Hansen, Jakob Werner Hansen, MD, Lene Sjö, Leonie Saft, MD PhD, Kirsten Grønbæk, Professor, MD DMSc

Blood (2018) 132 (Supplement 1): 3105.

https://doi.org/10.1182/blood-2018-99-114517

Published: 2018

Journal Articles

SF3B1 -initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells

Teresa Mortera-Blanco, Marios Dimitriou, Petter S. Woll, Mohsen Karimi, Edda Elvarsdottir, Simona Conte, Magnus Tobiasson, Monika Jansson, Iyadh Douagi, Matahi Moarii, Leonie Saft, Elli Papaemmanuil, Sten Eirik W. Jacobsen, Eva Hellström-Lindberg

Blood (2017) 130 (7): 881–890.

https://doi.org/10.1182/blood-2017-03-776070

Published: 2017

Includes: Supplemental data

Journal Articles

Progression in Patients with with Low- and Intermediate-1 Risk Del(5q) MDS Is Predicted By a Limited Subset of Mutations

Christian Scharenberg, MD, Petter S. Woll, PhD, Valentina Giai, MD PhD, Andrea Pellagatti, PhD, Leonie Saft, MD PhD, Marios Dimitriou, Martin Jädersten, Monika Jansson, Iyadh Douagi, PhD, Donna S. Neuberg, ScD, Mohsen Karimi, Katarina Le Blanc, MD, PhD, Jacqueline Boultwood, PhD, Sten Eirik Jacobsen, MD PhD, Eva Hellstrom-Lindberg, MD PhD

Blood (2016) 128 (22): 4329.

https://doi.org/10.1182/blood.V128.22.4329.4329

Published: 2016

Journal Articles

p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study

Leonie Saft, MD PhD, Jack Shiansong Li, PhD, Peter L. Greenberg, MD PhD, Mikkael A. Sekeres, MD MS, Guillermo F. Sanz, MD PhD, François Dreyfus, MD, Pierre Fenaux, MD PhD, Arlene S. Swern, PhD, Mary M. Sugrue, MD PhD, Eva Hellstrom-Lindberg, MD PhD

Blood (2014) 124 (21): 414.

https://doi.org/10.1182/blood.V124.21.414.414

Published: 2014

Journal Articles

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment

Christian Scharenberg, MD, Valentina Giai, MD, Andrea Pellagatti, PhD, Leonie Saft, MD, Goran Karlsson, PhD, Monika Jansson, Lalla Forsblom, Martin Jadersten, MD, PhD, Stefan Karlsson, M.D., Ph.D., Prof., Jacqueline Boultwood, PhD, Eva Hellstrom-Lindberg, MD, PhD

Blood (2011) 118 (21): 790.

https://doi.org/10.1182/blood.V118.21.790.790

Published: 2011

Journal Articles

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

Magnus Tobiasson, MD, Lena Brandefors, MD, Ingunn Dybedal, MD, PhD, Hege Garelius, MD, Michael Grövdal, MD, PhD, Inge Hoegh Dufva, MD, PhD, Lars Kjeldsen, MD, PhD, Lars Nilsson, MD, PhD, Astrid Olsnes Kittang, MD, PhD, Anna Porwit, MD, PhD, Leonie Saft, MD, Mette Skov Holm, MD, PhD, Lars Möllgård, MD, Phd, Eva Hellström-Lindberg

Blood (2011) 118 (21): 3798.

https://doi.org/10.1182/blood.V118.21.3798.3798

Published: 2011

Journal Articles

Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression

Martin Jädersten, Leonie Saft, Andrea Pellagatti, Gudrun Göhring, Cristina Fernández-Santamaria, James S Wainscoat, Jacqueline Boultwood, Anna Porwit, Brigitte Schlegelberger, Eva Hellström-Lindberg, MD, PhD

Blood (2008) 112 (11): 5104.

https://doi.org/10.1182/blood.V112.11.5104.5104

Published: 2008

NARROW

Multicenter Prospective Evaluation of Diagnostic Potential of Flow Cytometric Aberrancies in Myelodysplastic Syndromes

From Mild Cytopenia to Overt MDS and AML, the Mutational Profile Predicts Progression, but Not Survival

The Diagnostic Role of Flow Cytometry in Idiopathic Cytopenia of Unknown Significance (ICUS): A Single-Center Analysis of 79 Patients

SF3B1 -initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells

Progression in Patients with with Low- and Intermediate-1 Risk Del(5q) MDS Is Predicted By a Limited Subset of Mutations

p53 Mutant Independently Impacts Risk: Analysis of Deletion 5q, Lower-Risk Myelodysplastic Syndromes (MDS) Patients Treated with Lenalidomide (LEN) in the MDS-004 Study

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

Clonal Heterogeneity in the 5q- Syndrome: NPMc+ and p53 Expressing Progenitors Are Insensitive to Lenalidomide Treatment and Expand at Disease Progression

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only